Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeFiD trial of denosumab for painful fibrous dysplasia/McCune-Albright syndrome in adults
NL-OMON60105Phase 4Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in fibrous dysplasia and McCune-Albright syndrome (MAS) comparing Denosumab with Placebo (2 arms). Primary endpoint: Primary: change in maximum pain score at 6 months. Started Jun 2023; status: recruiting.
02
Drugs
denosumab
03
Conditions
fibrous dysplasiaMcCune-Albright syndrome (MAS)
Beyond the preview
Go deeper on NL-OMON60105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60105.